This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
10-03 :: March 2010

nanotimes

Companies

Facts

Tablets in the U.S. This action is in response to the March 17, 2010 approval of Dr. Reddy’s generic version of Allegra-D®

24 Hour by the FDA.

In September 2009, AMRI filed a patent infringe- ment lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy’s for infringement of one of AMRI’s patents related to the manufacturing process for the active ingredient in Allegra®

, Allegra-D® 12, and Allegra-D® 24 Hour,

which issued in 2008. Sanofi-aventis U.S. is now joining AMRI in this lawsuit. Regardless of the out- come of the preliminary injunction motion, AMRI will continue to forcefully and vigorously defend its intellectual property.

http://www.amriglobal.com

Co. Ltd. of Taiwan has placed a multiple order for AIXTRON’s latest MOCVD System, the AIX G5 HT, to expand their manufacturing capacity of high brightness light emitting diodes (HB-LEDs). The order was received, shortly after AIXTRON announced the launch of its next generation MOCVD systems AIX G5 HT and CRIUS II. Furthermore, the Company an- nounced an order for one Black Magic CNT deposi- tion system from the EMPA research institute, Swit- zerland. The order was received in the third quarter 2009 and the system will be delivered in the first quarter 2010 with the 1x2inch wafer configuration.

http://www.aixtron.com

A

conducted by majority-owned subsidiary, Calando

Pharmaceuticals, Inc., has demonstrated systemic

A

rrowhead Research Corporation (NASDAQ: ARWR) announced that the clinical trial being

IXTRON AG (NASDAQ: AIXG, ISIN: US0096061041) announced that Tekcore

delivery of siRNA and the successful “silencing” of a widely recognized cancer gene via RNA in- terference (RNAi) in humans. This represents a

breakthrough for Calando, its proprietary RONDEL™ delivery system, and the field of RNAi. It is thought to be the first ever demonstration in humans of targe- ted siRNA-containing nanoparticle delivery to tumors using systemic administration, delivery of functional siRNAs, and achievement of specific mRNA and protein reductions via RNAi. Thus far in the trial, no significant drug-related toxicities, known as serious adverse events (SAEs), have been observed that may limit use.

Mark E. Davis, Jonathan E. Zuckerman, Chung Hang J. Choi, David Seligson, Anthony Tolcher, Christopher A. Ala- bi, Yun Yen, Jeremy D. Heidel, Antoni Ribas: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles, In: Nature AOP; March 21, 2010, DOI:10.1038/nature08956: http://dx.doi.org/10.1038/nature08956

B

ayer MaterialScience LLC, a subsidiary of German Bayer AG (Bayer: BAYZF), has

acquired Artificial Muscle, Inc. (AMI) of Sunnyvale,

California. AMI was spun out of SRI (Stanford Re- search Institute) International, in early 2004 to com-

mercialize Electroactive Polymer Artificial Muscle (EPAM™) technology.

AMI initially targeted products for a range of appli- cations including valves, pumps, positioners, power generation and sensors. With the emergent need for haptics in consumer electronics, particularly in touchscreens, AMI used EPAM™ to create the Re- flex™ brand of haptic actuators. Now, AMI polymers are used in the development, design and manufac- ture of actuators and sensing components. Through

17 Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69